Quick Answer
Humacyte, Inc. reported Total Assets of $116.37 million for the year ending 2025.
- Humacyte, Inc. showed a decrease of -15.6% in Total Assets from 2024 to 2025.
- This data is from Humacyte, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $101.32 million | Q1 2021: $100.67 million | Q2 2021: $100.51 million | Q3 2021: $303.36 million | Q1 2022: $264.47 million | Q2 2022: $246.37 million | Q3 2022: $226.22 million | Q1 2023: $182.98 million | Q2 2023: $168.11 million | Q3 2023: $149.39 million | Q1 2024: $161.47 million | Q2 2024: $138.28 million | Q3 2024: $114.76 million | Q1 2025: $162.55 million | Q2 2025: $138.80 million | Q3 2025: $91.51 million.
- Over the full 6 years of available data (2020 to 2025), Humacyte, Inc.'s Total Assets has grown by 9.1%.
- Historical annual values: Fiscal year 2025: $116.37 million | Fiscal year 2024: $137.87 million | Fiscal year 2023: $128.22 million | Fiscal year 2022: $204.30 million | Fiscal year 2021: $286.53 million | Fiscal year 2020: $106.69 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: